

# EPICS

## Global Perspectives: Current and Future State of CAR T and Bispecific Antibodies in Hematologic Malignancies

Day 1: 27 June, 18.00 – 21.30 CEST / 11.00 AM – 2.30 PM CST, 3.5 hr

Day 2: 12 July, 18.00 – 21.00 CEST / 11.00 AM – 2.00 PM CST, 3 hr

Virtual Meeting

**Co-chairs:** Elias Jabbour, MD (US), and Marie-José Kersten, MD, PhD (Netherlands)

### Faculty

- DLBCL
  - Matthew Frigault, MD (US)
  - Olivier Tournilhac, MD, PhD (France)
- Indolent NHL
  - Caron A. Jacobson, MD, MMSc (US)
  - Paolo Corradini, MD (Italy)
  - Georg Hess, MD (Germany)
- Leukemia
  - Daniel DeAngelo, MD, PhD (US)
  - Nicola Gökbuget, MD (Germany)
- Multiple myeloma
  - Irene Ghobrial, MD (US)
  - Keith Stewart, MB, ChB (Canada)
  - Xavier Leleu, MD, PhD (France) – TBC

### Chairing roles proposal

- Day 1
  - CAR T in DLBCL – Dr Kersten
  - Bispecific Antibodies in B-NHL – Dr Kersten
  - CAR T in Indolent NHL/MCL and CLL – Dr Kersten
  - Break
  - CAR T in Leukemias – Dr Jabbour
  - Bispecific Antibodies in Leukemias – Dr Jabbour
- Day 2
  - CAR T in MM – Dr Jabbour
  - Bispecific Antibodies in MM – Dr Jabbour
  - Break
  - Real-world Data: Impact for the CAR T and Bispecific Antibodies Field – Dr Kersten
  - CAR T Adoption in the Real World – Dr Kersten

## Virtual Meeting Day 1

Time	Topic	Speaker
18.00 – 18.10 / 11.00 AM – 11.10 AM (10 min)	<b>Welcome and Introductions</b>	Marie-José Kersten, MD, PhD (Netherlands)
<b>CAR T in DLBCL</b>		
18.10 – 18.20 / 11.10 AM – 11.20 AM (10 min)	<b>Update on CAR T in DLBCL</b> <ul style="list-style-type: none"> <li>Brief review of current state and new clinical advances with CAR T in DLBCL <ul style="list-style-type: none"> <li>Axi-cel</li> <li>Tisa-cel</li> <li>Liso-cel</li> <li>Dual-targeting CAR Ts (eg, GC012F)</li> <li>Allogeneic CAR Ts</li> </ul> </li> </ul>	Olivier Tournilhac, MD PhD (France)
18.20 – 18.45 / 11.20 AM – 11.45 AM (25 min)	<b>Key Topics for Discussion</b> Updates on CAR T in DLBCL <ul style="list-style-type: none"> <li>In your opinion, what are the most impactful data on CAR T in DLBCL recently presented or awaited in the near future?</li> </ul> Current treatment landscape <ul style="list-style-type: none"> <li>Given that multiple CAR T therapies are approved in R/R DLBCL, what factors affect which CAR T construct would be prescribed, and why?</li> <li>What is known about patient/disease characteristics in DLBCL predictive of response or toxicity with CAR T-cell therapy? <ul style="list-style-type: none"> <li>How do these differ by patient subset and/or treatment line?</li> <li>Should older patients receive the same considerations for CAR T-cell therapy as younger patients? What is the current approach? Does it depend on the region?</li> </ul> </li> </ul> Future perspectives <ul style="list-style-type: none"> <li>How do you see the future of treatment sequencing in DLBCL? Will HSCT be replaced by CAR T? <ul style="list-style-type: none"> <li>What type of patients may be considered for CAR T in earlier lines?</li> <li>How do you treat late relapse, non-transplant eligible patients in 2nd line?</li> </ul> </li> <li>What role in DLBCL and lymphoma in general do you foresee for <ul style="list-style-type: none"> <li>Allogeneic CAR Ts?</li> <li>Bispecific CAR Ts?</li> <li>CAR-NKs?</li> </ul> </li> </ul>	All  Discussion moderated by Marie-José Kersten, MD, PhD (Netherlands)
18.45 – 18.50 / 11.45 AM – 11.50 AM (5 min)	<b>Summary of Key Takeaways: CAR T in DLBCL</b>	Olivier Tournilhac, MD PhD (France)

<b>Bispecific Antibodies in B-NHL</b>		
18.50 – 19.00 / 11.50 AM – 12.00 PM (10 min)	<p><b>Update on Bispecific Antibodies in B-NHL</b></p> <ul style="list-style-type: none"> <li>Brief review of current state and new clinical advances with bispecific antibodies in B-NHL <ul style="list-style-type: none"> <li>Blinatumomab</li> <li>Epcoritamab</li> <li>Glofitamab</li> <li>Mosunetuzumab</li> <li>Odronextamab</li> <li>Plamotamab</li> <li>IPH6501, a tetraspecific antibody-based NK cell engager</li> </ul> </li> <li>If time: Bispecific antibodies in CLL (eg, odronextamab)</li> </ul>	Georg Hess, MD (Germany)
19.00 – 19.20 / 12.00 PM – 12.20 PM (20 min)	<p><b>Key Topics for Discussion</b></p> <p>Updates on bispecific antibodies in B-NHL</p> <ul style="list-style-type: none"> <li>In your opinion, what are the most impactful data on bispecific antibodies in B-NHL recently presented or awaited in the near future?</li> </ul> <p>Future treatment landscape</p> <ul style="list-style-type: none"> <li>How will the data from the POLARIX trial influence treatment sequencing in B-NHL?</li> <li>How do the efficacy and tolerability of bispecific antibodies in B-NHL compare with CAR T-cell therapy? <ul style="list-style-type: none"> <li>Have any long-term AEs with bispecific antibodies emerged?</li> <li>How much do logistics play a role in selecting CAR T vs bispecific antibodies, and why?</li> </ul> </li> <li>What efficacy/safety results would you look for in bispecific agents in DLBCL vs indolent NHL?</li> <li>Are there any bispecific constructs that appear more effective than others?</li> <li>Bispecific antibodies for patients whose disease relapsed on CAR T – how promising is this approach?</li> </ul>	All  Discussion moderated by Marie-José Kersten, MD, PhD (Netherlands)
19.20 – 19.25 / 12.20 PM – 12.25 PM (5 min)	<b>Summary of Key Takeaways: Bispecific Antibodies in B-NHL</b>	Georg Hess, MD (Germany)
<b>CAR T in Indolent NHL/MCL</b>		
19.25 – 19.45 / 12.25 PM – 12.45 PM (20 min)	<p><b>Update on CAR T in Indolent NHL/MCL and CLL</b></p> <ul style="list-style-type: none"> <li>Brief review of current state and new clinical advances with CAR T in indolent NHL and CLL <ul style="list-style-type: none"> <li>Brexu-cel</li> <li>Axi-cel</li> <li>Tisa-cel</li> <li>Liso-cel</li> </ul> </li> </ul>	Caron A. Jacobson, MD, MMSc (US)

<p>19.45 – 20.10 / 12.45 PM – 1.10 PM (25 min)</p>	<p><b>Key Topics for Discussion</b> Updates on CAR T in indolent NHL</p> <ul style="list-style-type: none"> <li>In your opinion, what are the most impactful data on CAR T in indolent NHL recently presented or awaited in the near future?</li> </ul> <p>Current and future treatment landscape</p> <ul style="list-style-type: none"> <li>How will the data from the TRANSCEND trials (FL, NHL 001, CLL 004) influence treatment sequencing in indolent NHL and CLL?</li> <li>Are there patient/disease characteristics in FL and MCL predictive of response to CAR T cells? Are they different compared with DLBCL?</li> <li>How to position CAR T-cell therapy in FL <ul style="list-style-type: none"> <li>Have differences emerged between the various investigated constructs?</li> <li>What is the potential for CAR T-cell therapy to move earlier in the treatment sequence in earlier-stage disease?</li> </ul> </li> <li>How has the approval of CAR T-cell therapy changed the treatment landscape in MCL? <ul style="list-style-type: none"> <li>In which patients would you consider BTKi as a bridge to CAR T-cell therapy?</li> <li>Are there any patients for whom you would consider CAR T-cell therapy before a BTKi?</li> <li>Is there a rationale for combining CAR T with other agents in MCL, such as BTKi?</li> </ul> </li> <li>What role do you foresee for CAR Ts in CLL?</li> </ul>	<p>All</p> <p>Discussion moderated by Marie-José Kersten, MD, PhD (Netherlands)</p>
<p>20.10 – 20.15 / 1.10 PM – 1.15 PM (5 min)</p>	<p><b>Summary of Key Takeaways: CAR T in Indolent NHL/MCL and CLL</b></p>	<p>Caron A. Jacobson, MD, MMSc (US)</p>
<p>20.15 – 20.20 / 1.15 PM – 1.20 PM (5 min)</p>	<p><b>BREAK</b></p>	
<p><b>CAR T in Leukemias</b></p>		
<p>20.20 – 20.30 / 1.20 PM – 1.30 PM (10 min)</p>	<p><b>Update on CAR T in Leukemias</b></p> <ul style="list-style-type: none"> <li>Brief review of current state and new clinical advances with CAR T in leukemias <ul style="list-style-type: none"> <li>Tisa-cel (ALL)</li> <li>Brexu-cel (ALL)</li> <li>Dual-targeting CAR Ts (ALL)</li> <li>Allogeneic CAR Ts (ALL)</li> <li>CAR Ts in AML (eg, KITE-222, MLM-CAR44)</li> <li>If time: CAR Ts in CLL (eg, liso-cel)</li> </ul> </li> </ul>	<p>Daniel DeAngelo, MD, PhD (US)</p>

<p>20.30 – 20.50 / 1.30 PM – 1.50 PM (20 min)</p>	<p><b>Key Topics for Discussion</b> Updates on CAR T in leukemias</p> <ul style="list-style-type: none"> <li>In your opinion, what are the most impactful data on CAR T in ALL recently presented or awaited in the near future?</li> </ul> <p>Current and future treatment landscape in ALL</p> <ul style="list-style-type: none"> <li>What is known about patient/disease characteristics in ALL predictive of response or toxicity with CAR T-cell therapy? <ul style="list-style-type: none"> <li>How do these differ by patient subset?</li> <li>How do these differ compared with lymphomas?</li> </ul> </li> <li>How does MRD status affect treatment with CAR Ts?</li> <li>How will the relationship between CAR Ts and HSCT evolve?</li> <li>How do we overcome resistance to CAR T-cell therapy? Is reinfusion a feasible approach?</li> <li>What is the role of CAR T-cell therapy in patients &gt;25 years old with ALL? What are the perspectives in the pediatric setting?</li> <li>Should blinatumomab or inotuzumab ozogamicin move into the frontline setting, how will this affect the use of CAR T-cell therapy?</li> <li>Could CAR T be used as bridge to allo-transplant, or is it a definitive therapy?</li> </ul> <p>Future treatment landscape in AML</p> <ul style="list-style-type: none"> <li>How is CAR T-cell therapy progressing in AML, and how promising is this approach in AML?</li> <li>Which cell-surface targets are most promising in AML (eg, CLL-1, CD33, FLT3)? <ul style="list-style-type: none"> <li>What are the major on-target/off-target toxicities with each?</li> </ul> </li> </ul>	<p>All</p> <p>Discussion moderated by Elias Jabbour, MD (US)</p>
<p>20.50 – 20.55 / 1.50 PM – 1.55 PM (5 min)</p>	<p><b>Summary of Key Takeaways: CAR T in Leukemias</b></p>	<p>Daniel DeAngelo, MD, PhD (US)</p>
<p><b>Bispecific Antibodies in Leukemias</b></p>		
<p>20.55 – 21.05 / 1.55 PM – 2.05 PM (10 min)</p>	<p><b>Update on Bispecific Antibodies in Leukemias</b></p> <ul style="list-style-type: none"> <li>Brief review of current state and new clinical advances with bispecific antibodies in leukemias <ul style="list-style-type: none"> <li>Blinatumomab alone and in combination</li> <li>Bispecific antibodies in AML (eg, AMG 330, AMG 427, AMG 673, ABBV-184)</li> </ul> </li> </ul>	<p>Nicola Gökbüget, MD (Germany)</p>
<p>21.05 – 21.20 / 2.05 PM – 2.20 PM (15 min)</p>	<p><b>Key Topics for Discussion</b> Updates on bispecific antibodies in leukemias</p> <ul style="list-style-type: none"> <li>In your opinion, what are the most impactful data on bispecific antibodies in ALL recently presented or awaited in the near future?</li> </ul> <p>Current and future treatment landscape in ALL</p>	<p>All</p> <p>Discussion moderated by Elias Jabbour, MD (US)</p>

	<ul style="list-style-type: none"> <li>• What benchmarks need to be met for first-line use of blinatumomab in ALL?</li> <li>• What are the prospects of a chemotherapy-free approach in ALL (eg, blinatumomab-inotuzumab)? Or blinatumomab-ponatinib in Ph-positive ALL?</li> <li>• How do you reconcile the increasing sensitivity of MRD assays? Is there a “safe” level below which transplant can be avoided in patients with ALL who receive blinatumomab?</li> </ul> <p>Future treatment landscape in AML</p> <ul style="list-style-type: none"> <li>• How are bispecific antibodies progressing in AML, and how promising is this approach in AML?</li> </ul>	
21.20 – 21.25 / 2.20 PM – 2.25 PM (5 min)	<b>Summary of Key Takeaways: Bispecific Antibodies in Leukemias</b>	Nicola Gökbüget, MD (Germany)
21.25 – 21.30 / 2.25 PM – 2.30 PM (5 min)	<b>Closing Remarks</b>	Elias Jabbour, MD (US)

## Virtual Meeting Day 2

Time	Topic	Speaker
18.00 – 18.05 / 11.00 AM – 11.05 AM (5 min)	<b>Welcome and Introduction</b>	Elias Jabbour, MD (US)
<b>CAR T in MM</b>		
18.05 – 18.15 / 11.05 AM – 11.15 AM (10 min)	<b>Update on CAR T in MM</b> <ul style="list-style-type: none"> <li>• Brief review of current state and new clinical advances with CAR T in MM <ul style="list-style-type: none"> <li>– Ide-cel</li> <li>– bb21217</li> <li>– Cilta-cel</li> <li>– P-BCMA-101</li> <li>– Allogeneic CAR Ts</li> </ul> </li> </ul>	Irene Ghobrial, MD (US)
18.15 – 18.35 / 11.15 AM – 11.35 AM (20 min)	<b>Key Topics for Discussion</b> Updates on CAR T in MM <ul style="list-style-type: none"> <li>• In your opinion, what are the most impactful data on CAR T in MM recently presented or awaited in the near future?</li> </ul> Current and future treatment landscape <ul style="list-style-type: none"> <li>• Where does CAR T-cell therapy best fit within the MM treatment landscape? Which patient population? <ul style="list-style-type: none"> <li>– How has the recent approval of ide-cel impacted the treatment landscape in MM?</li> <li>– What are the biggest challenges for uptake of CAR T in MM?</li> </ul> </li> </ul>	All  Discussion moderated by Elias Jabbour, MD (US)

	<ul style="list-style-type: none"> <li>• How do toxicities associated with CAR T-cell therapy compare with other BCMA-targeting agents (bispecific antibodies, ADC)? <ul style="list-style-type: none"> <li>– Which ones are the most challenging to manage for each agent class?</li> <li>– How do they affect the selection of treatment?</li> </ul> </li> <li>• How will the recent analyses from the KarMMA-3 trial influence treatment sequencing in MM?</li> <li>• MRD status in MM – how does it affect T-cell-directed strategies?</li> <li>• Is there a rationale for maintenance therapy post-CAR T? What are the most promising maintenance strategies, and why?</li> <li>• Beyond BCMA, what are the most promising new targets for CAR T cells in MM?</li> <li>• How are allogeneic CAR Ts progressing in MM?</li> <li>• Are dual-targeting CAR Ts a viable approach in MM?</li> </ul>	
18.35 – 18.40 / 11.35 AM – 11.40 AM (5 min)	<b>Summary of Key Takeaways: CAR T in MM</b>	Irene Ghobrial, MD (US)
<b>Bispecific Antibodies in MM</b>		
18.40 – 18.50 / 11.40 AM – 11.50 AM (10 min)	<b>Update on Bispecific Antibodies in MM</b> <ul style="list-style-type: none"> <li>• Brief review of current state and new clinical advances with bispecific antibodies in MM <ul style="list-style-type: none"> <li>– BCMA targeted <ul style="list-style-type: none"> <li>▪ CC-93269</li> <li>▪ Elranatamab</li> <li>▪ Pavurutamab (AMG 701)</li> <li>▪ REGN5458</li> <li>▪ Teclistamab</li> <li>▪ TNB-383B</li> </ul> </li> <li>– GPRC5D targeted (eg, talquetamab)</li> <li>– FcRH5 targeted (eg, cevostamab)</li> </ul> </li> </ul>	Keith Stewart, MB, ChB (Canada)
18.50 – 19.10 / 11.50 AM – 12.10 PM (20 min)	<b>Key Topics for Discussion</b> Updates on bispecific antibodies in MM <ul style="list-style-type: none"> <li>• In your opinion, what are the most impactful data on bispecific antibodies in MM recently presented or awaited in the near future?</li> </ul> Future treatment landscape <ul style="list-style-type: none"> <li>• Where do bispecific antibodies best fit within the MM treatment landscape? In which patient populations? <ul style="list-style-type: none"> <li>– Where do you see the positioning of bispecific antibodies relative to CAR T in MM? Why?</li> </ul> </li> </ul>	All  Discussion moderated by Elias Jabbour, MD (US)

	<ul style="list-style-type: none"> <li>– How would you choose between a BCMA-targeted bispecific antibody vs ADC vs CAR T?</li> <li>• What is the evidence supporting sequencing of CAR T vs bispecific antibodies?</li> <li>• Is the safety profile of bispecific antibodies in MM one that would be amenable to combinations with other classes of agents? If yes, which ones?</li> <li>• What is your opinion on targets other than BCMA (eg, FcRH5, GPRC5D)?</li> </ul>	
19.10 – 19.15 / 12.10 PM – 12.15 PM (5 min)	<b>Summary of Key Takeaways: Bispecific Antibodies in MM</b>	Keith Stewart, MB, ChB (Canada)
19.15 – 19.20 / 12.15 PM – 12.20 PM (5 min)	<b>BREAK</b>	
<b>Real-world Data: Impact for the CAR T and Bispecific Antibodies Field</b>		
19.20 – 19.30 / 12.20 PM – 12.30 PM (10 min)	<b>Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies</b> <ul style="list-style-type: none"> <li>• Brief discussion of the value of real-world data in the field of CAR T-cell therapies and bispecific antibodies and how these can complement data from clinical trials</li> </ul>	Paolo Corradini, MD (Italy)
19.30 – 19.50 / 12.30 PM – 12.50 PM (20 min)	<b>Key Topics for Discussion</b> <ul style="list-style-type: none"> <li>• How do efficacy/safety outcomes from pivotal trials with CAR T compare with data sets from the real world?</li> <li>• What have we learned from real-world use vs pivotal trials with CAR T? <ul style="list-style-type: none"> <li>– What are the implications for clinical practice?</li> </ul> </li> <li>• How can real-world evidence best complement data from clinical trials to inform clinicians, patients, regulatory authorities, and payors? <ul style="list-style-type: none"> <li>– Can real-world evidence from indications with more data available inform new and emerging indications (eg, MM)?</li> </ul> </li> <li>• The importance of reporting – how can existing registries best capture real-world data on CAR T-cell therapy? <ul style="list-style-type: none"> <li>– What are potential barriers, and how can we improve them?</li> </ul> </li> <li>• How does real-world experience with bispecific antibodies compare with CAR T?</li> <li>• Which real-world studies would you like to see conducted?</li> </ul>	All  Discussion moderated by Marie-José Kersten, MD, PhD (Netherlands)



19.50 – 19.55 / 12.50 PM – 12.55 PM (5 min)	<b>Summary of Key Takeaways: Impact of Real-world Data on CAR T-Cell Therapies</b>	Paolo Corradini, MD (Italy)
<b>CAR T Adoption in the Real World</b>		
19.55 – 20.05 / 12.55 PM – 1.05 PM (10 min)	<b>Sharing Experiences: Current Barriers for Real-world CAR T Adoption in the US</b> <ul style="list-style-type: none"> <li>• Brief insight into the US real-life experience regarding adoption of CAR T and potential barriers to access, including <ul style="list-style-type: none"> <li>– Patient referral</li> <li>– Payor authorization and reimbursement</li> <li>– Patient and caregiver out-of-pocket costs</li> <li>– CAR T-cell manufacturing</li> <li>– Geographic access to CAR T-cell therapy centers</li> </ul> </li> </ul>	Matthew Frigault, MD (US)
20.05 – 20.15 / 1.05 PM – 1.15 PM (10 min)	<b>Sharing Experiences: Current Barriers for Real-world CAR T Adoption in Europe</b> <ul style="list-style-type: none"> <li>• Brief insight into the European real-life experience regarding adoption of CAR T and potential barriers to access including <ul style="list-style-type: none"> <li>– Patient referral</li> <li>– Payor authorization and reimbursement</li> <li>– Patient and caregiver out-of-pocket costs</li> <li>– CAR T-cell manufacturing</li> <li>– Geographic access to CAR T-cell therapy centers</li> </ul> </li> </ul>	Xavier Leleu, MD PhD (France)
20.15 – 20.45 / 1.15 PM – 1.45 PM (30 min)	<b>Key Topics for Discussion</b> <ul style="list-style-type: none"> <li>• What opportunities do you see for increasing access and use of CAR T-cell therapy?</li> <li>• What are typical referral patterns and drivers of referral? <ul style="list-style-type: none"> <li>– What barriers to referral for CAR T-cell therapy exist, and how can we overcome them?</li> </ul> </li> <li>• What challenges do you face regarding reimbursement and pricing? <ul style="list-style-type: none"> <li>– How much of pricing/cost is a barrier to access?</li> </ul> </li> <li>• What challenges do you face regarding CAR T manufacturing? <ul style="list-style-type: none"> <li>– What is the typical turnaround time for commercially available CAR T products?</li> <li>– What key factors in leukapheresis and cell processing affect the quality and success of CAR T manufacturing? <ul style="list-style-type: none"> <li>▪ Are there specific treatments or practices that you consider particularly deleterious to T-cell function?</li> </ul> </li> </ul> </li> </ul>	All  Discussion moderated by Marie-José Kersten, MD, PhD (Netherlands)

	<ul style="list-style-type: none"> <li>- Is there a benefit for early cryopreservation of T cells? For which patients would you consider this approach? <ul style="list-style-type: none"> <li>▪ What prevents you from collecting and cryopreserving leukapheresis material early in the course of the disease, and how can this be overcome?</li> </ul> </li> <li>- Current efforts to shorten manufacturing times – what is your opinion on these strategies? Which are the most promising?</li> <li>• What is the flexibility of patient flow across different countries?</li> </ul>	
20.45 – 20.55 / 1.45 PM – 1.55 PM (10 min)	<b>Summary of Key Takeaways: Real-world CAR T Adoption</b>	Matthew Frigault, MD (US), and – Xavier Leleu, MD PhD (France)
20.55 – 21.05 / 1.55 PM – 2.00 PM (5 min)	<b>Closing Remarks</b>	Marie-José Kersten, MD, PhD (Netherlands)